Brief Article
Copyright ©2010 Baishideng.
World J Gastroenterol. May 28, 2010; 16(20): 2526-2530
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2526
Figure 1
Figure 1 Disease-free survival (DFS) (A) and overall survival (OS) (B) curve. Group A: Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); Group B: Rituximab plus chemotherapy.